- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Roundtable Discussion: Hamilton Compares Therapy Options and Sequencing for Recurrent TNBC
September 25, 2022
During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.
Atezolizumab Added to SOC in HER2-Positive Breast Cancer Does Not Increase Responses
September 24, 2022
Pertuzumab plus trastuzumab and chemotherapy remains the standard of care for HER2-positive breast cancer, after the addition of atezolizumab did not benefit responses in the Impassion050 study.
Clinical Activity Is Found With Triplet Combination and ADCs in HER2-Mutant MBC
September 24, 2022
Results from the SUMMIT basket study revealed encouraging results with a neratinib triplet regimen in patients with HR-positive/ HER2-negative metastatic breast cancer compared with other variations and monotherapies of the 3 drugs.
Roundtable Discussion: Considerations of Transplant and JAK Inhibition Guide Treatment for a Patient With Myelofibrosis
September 24, 2022
During a Targeted Oncology case-based roundtable event, Andrew Kuykendall, MD, discussed the treatment options for a patient with myelofibrosis based on factors including platelet count.
Omidubicel Increases Availability of Allogeneic Stem Cell Transplant
September 23, 2022
Chenyu Lin, MD, discusses the significance of a 10-year follow up of a study of patients who underwent allogeneic stem cell transplant with the novel cell therapy omidubicel.
Key Factors Influence Treatment in Chemotherapy-, AR-Refractory mCRPC
September 23, 2022
During a live virtual event, Edwin M. Posadas, MD, discussed patient factors for choosing the type of therapy to use after progression on androgen receptor therapy and chemotherapy with participants.
ODAC Votes Against Duvelisib for Relapsed or Refractory CLL/SLL
September 23, 2022
A 5-year overall survival analysis led the FDA to question duvelisib for relapsed or refractory chronic lymphocytic leukemia. ODAC members voted that the benefit-risk profile of the drug is not favorable.
Neoadjuvant Combination Improves MRD Rates in High-Risk Prostate Cancer
September 23, 2022
Positive findings were reported from the phase 2 ARNEO trial during the European Association of Urology Congress 2022.
LEAP-002 Trial of Lenvatinib/Pembrolizumab Combo Misses Key End Points in uHCC
September 23, 2022
In an interview with Targeted Oncology Richard Finn, MD, discussed the implications of the LEAP-002 trial.
Optimizing Dosing of First-Line IO-TKI Therapy in Advanced RCC
September 23, 2022
Shared insight on optimal dosing strategies with first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced clear cell renal cell carcinoma.
First-Line Treatment for Advanced RCC: Cabozantinib + Nivolumab
September 23, 2022
Sumanta Pal, MD, an expert hematologist/oncologist, evaluates the combination of cabozantinib + nivolumab as first-line therapy for advanced clear cell renal cell carcinoma.
Toripalimab and Chemotherapy Combination Reveals Promising Efficacy for UTUC
September 23, 2022
The combination of toripalimab and chemotherapy displayed promising efficacy results in a phase 2 study.